Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe plus atorvastatin versus higher-dose atorvastatin or rosuvastatin in high-risk primary hypercholesterolemia
NL-OMON38112Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing Ezetimibe + atorvastatin sequence, Atorvastatin sequence and Rosuvastatin sequence (3 arms). Primary endpoints: LDL-C percentage reduction at end of Phase I: ezetimibe + atorvastatin versus atorvastatin 20 mg and LDL-C percentage reduction at end of Phase I: ezetimibe + atorvastatin versus rosuvastatin 10 mg. Started Feb 2011; status: active, not recruiting.
02
Drugs
ezetimibeatorvastatinrosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON38112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38112.